Patient-derived tumor explant models of tumor immune microenvironment reveal distinct and reproducible immunotherapy responses
Authors:
Open Access
- 17 February 2025
- journal article
- Published by Taylor & Francis in OncoImmunology
- Vol. 14 (1) , 2466305
Abstract
Tumor-resident immune cells play a crucial role in eliciting anti-tumor immunity and immunomodulatory drug responses, yet these functions have been difficult to study without tractable models of the tumor immune microenvironment (TIME). Patient-derived ex vivo models contain authentic resident immune cells and therefore, could provide new mechanistic insights into how the TIME responds to tumor or immune cell-directed therapies. Here, we assessed the reproducibility and robustness of immunomodulatory drug responses across two different ex vivo models of breast cancer TIME and one of renal cell carcinoma. These independently developed TIME models were treated with a panel of clinically relevant immunomodulators, revealing remarkably similar changes in gene expression and cytokine profiles among the three models in response to T cell activation and STING-agonism, while still preserving individual patient-specific response patterns. Moreover, we found two common core signatures of adaptive or innate immune responses present across all three models and both types of cancer, potentially serving as benchmarks for drug-induced immune activation in ex vivo models of the TIME. The robust reproducibility of immunomodulatory drug responses observed across diverse ex vivo models of the TIME underscores the significance of human patient-derived models in elucidating the complexities of anti-tumor immunity and therapeutic interventions.Keywords
All Related Versions
Funding Information
- Business Finland Health program
- Academy of Finland, Business Finland
- Sihtasutus Archimedes, Ida Montinin Säätiö, Finnish Cancer Institute, Syöpäjärjestöt
- iCAN Digital Precision Cancer Medicine Flagship
This publication has 34 references indexed in Scilit:
- The inflammatory/cancer-related IL-6/STAT3/NF-κB positive feedback loop includes AUF1 and maintains the active state of breast myofibroblastsOncotarget, 2016
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancerOncoImmunology, 2015
- Role of the Tumor Microenvironment in Breast CancerPathobiology, 2015
- Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and ImmunityCell Reports, 2015
- IL-6 as a keystone cytokine in health and diseaseNature Immunology, 2015
- Interleukin-6 signaling pathway in targeted therapy for cancerCancer Treatment Reviews, 2012
- Type I interferon is selectively required by dendritic cells for immune rejection of tumorsJournal of Experimental Medicine, 2011
- Boolean implication networks derived from large scale, whole genome microarray datasetsGenome Biology, 2008
- Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancerHuman Pathology, 2007